Abstract
Photodynamic therapy implies a combined use of a photosensitizing medicament and low-intensity light to cause selective damage to the target tissue—tumor. As potential medicament, we use Ru(II)(dcbpy)2Cl2 complex, and in order to achieve better photosensitization properties, the Ru complex was attached to the nano carrier—TiO2 nanoparticles. Additionally, this nanocomposite system was encapsulated in the phospholipid vesicles, which could be classified as small unilamellar vesicles, based on the technique of production. The complex-release tests were performed under light illumination, at pH 5, characteristic for tumor cells` interior and compared with the release pattern at pH 7, characteristic for the serum, i.e. physiological solution.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
